Birinci ve İkinci Trimester Tarama Testlerinde Kullanılan Biyokimyasal Belirteçlerin Kötü Obstetrik Sonuçlarla İlişkisi
Abstract
Objectives: This study aims to determine the relationship between poor obstetric and perinatal outcomes and maternal serum aneuploidy markers
of first and second trimesters.
Materials and Methods: Five hundred three singleton pregnancies who underwent prenatal screening for aneuploidy were examined. The
association between serum aneuploidy markers and poor obstetric and perinatal outcomes was investigated. In the regression analysis, adjusted
odds ratio, 95% confidence interval and p-values were found for each marker.
Results: The median Multiple of the Median (MoM) of pregnancy-associated plasma protein A was significantly lower in pregnancies with pregnancy
induced hypertension (0.63 vs 0.89, p=0.014). Women with elevated free β human chorionic gonadotropin (hCG) MoM levels were more likely to
experience intrauterine growth retardation (p=0.029). By examining low (≤10th percentile) alpha fetoprotein (AFP) MoM levels, we found a 9 fold
increase in risk of fetal death at or after 24 weeks of gestation (p=0.036). In case of high AFP levels, 5 fold increase in risk of IUGR was observed
(p=0.023). While decreased levels of second-trimester hCG were associated with IUGR (p=0.011), increased risk of pregnancy induced hypertension
was significantly associated with elevated hCG levels (p=0.001). Increased risk of abruptio placentae was associated with elevated hCG levels
(p=0.023). Low levels of unconjugated estriol (uE3) appeared to be associated with pregnancy induced hypertension and low birth weight, the risks
of which increased as depressed levels of uE3 became more extreme. Elevated hCG (31% vs 6%, p<0.001) and low uE3 (16.3% vs 6.2%, p=0.025)
levels were associated with more need for neonatal intensive care in newborns. Reduced uE3 levels (at or below 10th percentile) were correlated
with lower gestational age at birth (38.4 vs 39, p=0.038).
Conclusion: A relationship was found between abnormal values of markers used in first and second trimester screening tests and poor obstetric
results. Triple screening hCG has been determined to be the best marker for predicting pregnancy induced hypertensive diseases.
Keywords
Prenatal Screening Test, Aneuploidy Markers, Adverse Pregnancy Outcomes, Perinatal Outcomes
References
- 1. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med. 2005;353:2001-2011.
- 2. Alldred SK, Takwoingi Y, Guo B, et al. First and second trimester serum tests with and without first trimester ultrasound tests for Down’s syndrome screening. Cochrane Database Syst Rev. 2017;3:CD012599.
- 3. Alamillo CM, Krantz D, Evans M, et al. Nearly a third of abnormalities found after first-trimester screening are different than expected: 10-year experience from a single center. Prenat Diagn. 2013;33:251-256.
- 4. Kazerouni NN, Currier RJ, Hodgkinson C, et al. Ancillary benefits of prenatal maternal serum screening achieved in the California program. Prenat Diagn. 2010;30:981-987.
- 5. Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (The FASTER Trial). Am J Obstet Gynecol. 2004;191:1446-1451.
- 6. Krantz D, Goetzl L, Simpson JL, et al. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other ad verse pregnancy outcomes. Am J Obstet Gynecol. 2004;191:1452-1458.
- 7. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics and the Society forMaternal-FetalMedicin. ACOG Practice Bulletin No. 204: Fetal Growth Restriction. Obstet Gynecol. 2019;133:97-109.
- 8. No authors listed. Practice Bulletin No. 145: Antepartum Fetal Surveillance. Obstet Gynecol. 2014;124:182-192.
- 9. No authors listed. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019;133:1.
- 10. American Diabetes Association. Erratum. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016;39(Suppl.1):S13-S22.